Search Results - "Visser, Sandra A G"

Momelotinib: Mechanism of action, clinical, and translational science by Vlasakakis, Georgios, McCabe, Michael T., Ho, Yu Liu, Ferron‐Brady, Geraldine, Martin, Paul, Bentley, Darren, Ellis, Catherine, Antonysamy, Mary, Visser, Sandra A. G.

“…Myelofibrosis is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, splenomegaly, anemia, and constitutional symptoms, with a median…”
Get full text

In memoriam Lambertus (“Bert”) A. Peletier 29 March 1937–16 December 2023: Furthering quantitative pharmacology through applied mathematics by Danhof, Meindert, Graaf, Piet H., Post, Teun M., Visser, Sandra A. G., Zuideveld, Klaas P., Schmidt, Stephan

“…Together with Bert, they started reviewing high-density pharmacological response versus time profiles from LACDR's portfolio, discussing the underlying…”
Get full text

Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid by Välitalo, Pyry A. J., Griffioen, Koen, Rizk, Matthew L., Visser, Sandra A. G., Danhof, Meindert, Rao, Gaori, van der Graaf, Piet H., van Hasselt, J. G. Coen

“…Purpose Obtaining pharmacologically relevant exposure levels of antibiotics in the epithelial lining fluid (ELF) is of critical importance to ensure optimal…”
Get full text

Systems Pharmacology Modeling of Drug-Induced Modulation of Thyroid Hormones in Dogs and Translation to Human by Ekerot, Petra, Ferguson, Douglas, Glämsta, Eva-Lena, Nilsson, Lars B., Andersson, Håkan, Rosqvist, Susanne, Visser, Sandra A. G.

“…ABSTRACT Purpose To develop a systems pharmacology model based on hormone physiology and pharmacokinetic-pharmacodynamic concepts describing the impact of…”
Get full text

In Vivo and Ex Vivo Inhibition of Spinal Nerve Ligation-Induced Ectopic Activity by Sodium Channel Blockers Correlate to In Vitro Inhibition of NaV1.7 and Clinical Efficacy: A Pharmacokinetic-Pharmacodynamic Translational Approach by Kalezic, Ivana, Luo, Lei, Lund, Per-Eric, Eriksson, Anders B, Bueters, Tjerk, Visser, Sandra A. G.

“…Purpose In vivo and ex vivo inhibition of ectopic activity of clinically used and newly developed sodium channel (NaV) blockers were quantified in the rat…”
Get full text

How debunking biases in research and development decisions could lead to more equitable healthcare? by Weber, Benjamin, Zineh, Issam, Lalonde, Richard, Visser, Sandra A. G.

“…Decades of research have demonstrated that a variety of cognitive biases can affect our judgment and ability to make rational decisions in personal and…”
Get full text

Building an adaptive dose simulation framework to aid dose and schedule selection by Hooijmaijers, Richard, Parasrampuria, Ridhi, Marostica, Eleonora, Ferron‐Brady, Geraldine, Post, Teun M., Visser, Sandra A. G.

“…Establishing a dosing regimen that maximizes clinical benefit and minimizes adverse effects for novel therapeutics is a key objective for drug developers…”
Get full text

Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making by Turner, David C., Wada, Russ, Zhou, Helen, Wang, Xiaowei, Greef, Rik, Valiathan, Chandni, Zhang, Lindsey, Zhang, Nancy, Kuchimanchi, Mita, Chen, Tai‐Tsang, Ballas, Marc, Visser, Sandra A. G.

“…Single‐arm cohorts/trials are often used in early phase oncology programs to support preliminary clinical activity assessments for investigational products,…”
Get full text

Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data by Niva, Camilla, Parkinson, Joanna, Olsson, Fredrik, van Schaick, Erno, Lundkvist, Johan, Visser, Sandra A. G.

“…Purpose To date, γ-secretase inhibition is the most frequently studied mechanism of reducing Aβ in clinical trials with as yet no therapeutic success for AD…”
Get full text

Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery by Bueters, Tjerk, Gibson, Christopher, Visser, Sandra A G

“…In this perspective article, we explain how quantitative and translational pharmacology, when well-implemented, is believed to lead to improved clinical…”
Get full text

Interplay between α-, β-, and γ-Secretases Determines Biphasic Amyloid-β Protein Level in the Presence of a γ-Secretase Inhibitor by Ortega, Fernando, Stott, Jonathan, Visser, Sandra A.G., Bendtsen, Claus

“…Amyloid-β (Aβ) is produced by the consecutive cleavage of amyloid precursor protein (APP) first by β-secretase, generating C99, and then by γ-secretase. APP is…”
Get full text

Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans by Aulin, Linda B. S., Valitalo, Pyry A., Rizk, Matthew L., Visser, Sandra A. G., Rao, Gauri, van der Graaf, Piet H., van Hasselt, J. G. Coen

Get full text

Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma-secretase inhibitor MRK-560 as detected by manganese-enhanced MRI by Wang, Fu-Hua, Appelkvist, Paulina, Klason, Tomas, Gissberg, Olle, Bogstedt, Anna, Eliason, Kristina, Martinsson, Stefan, Briem, Sveinn, Andersson, Anders, Visser, Sandra A. G., Ivarsson, Magnus, Lindberg, Mattias, Agerman, Karin, Sandin, Johan

“…Neuropil deposition of beta‐amyloid (Aβ) peptides is believed to be a key event in the neurodegenerative process of Alzheimer’s disease (AD). An early and…”
Get full text

Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies by Jewell, Roxanne C., Mills, Richard J., Farrell, Colm, Visser, Sandra A. G.

“…Aims To evaluate relationships between plasma concentrations of belantamab mafodotin, total monoclonal antibody, and its payload and changes in…”
Get full text

Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions by Caniga, Michael, Cabal, Antonio, Mehta, Khamir, Ross, David S, Gil, Malgorzata A, Woodhouse, Janice D, Eckman, Joseph, Naber, John R, Callahan, Marissa K, Goncalves, Luciano, Hill, Susan E, Mcleod, Robbie L, McIntosh, Fraser, Freke, Mark C, Visser, Sandra A G, Johnson, Neil, Salmon, Michael, Cicmil, Milenko

“…Understanding the relationship between dose, lung exposure, and drug efficacy continues to be a challenging aspect of inhaled drug development. An experimental…”
Get more information

Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels In Vivo and Correlation to In Vitro Potency in Primary Cortical Neurons from Mouse and Guinea Pig by Janson, Juliette, Eketjäll, Susanna, Tunblad, Karin, Jeppsson, Fredrik, Von Berg, Stefan, Niva, Camilla, Radesäter, Ann-Cathrin, Fälting, Johanna, Visser, Sandra A. G.

“…ABSTRACT Purpose The aims were to quantify the in vivo time-course between the oral dose, the plasma and brain exposure and the inhibitory effect on Amyloid β…”
Get full text

A Model‐Informed Drug Discovery and Development Strategy for the Novel Glucose‐Responsive Insulin MK‐2640 Enabled Rapid Decision Making by Visser, Sandra A.G., Kandala, Bhargava, Fancourt, Craig, Krug, Alexander W., Cho, Carolyn R.

“…A model‐informed drug discovery and development strategy played a key role in the novel glucose‐responsive insulin MK‐2640’s early clinical development…”
Get full text

Pharmacokinetic-Pharmacodynamic Modeling of the Inhibitory Effects of Naproxen on the Time-Courses of Inflammatory Pain, Fever, and the Ex Vivo Synthesis of TXB2 and PGE2 in Rats by Krekels, Elke H. J., Angesjö, Marie, Sjögren, Ingemo, Ängeby Möller, Kristina, Berge, Odd-Geir, Visser, Sandra A. G.

“…ABSTRACT Purpose To quantify and compare the time-course and potency of the analgesic and antipyretic effects of naproxen in conjunction with the inhibition of…”
Get full text

Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives by Marshall, Scott, Madabushi, Rajanikanth, Manolis, Efthymios, Krudys, Kevin, Staab, Alexander, Dykstra, Kevin, Visser, Sandra A.G.

“…Good practices around model‐informed drug discovery and development (MID3) aim to improve the implementation, standardization, and acceptance of these…”
Get full text

Clinical Evaluation of MK‐2640: An Insulin Analog With Glucose‐Responsive Properties by Krug, Alexander W., Visser, Sandra A.G., Tsai, Kuenhi, Kandala, Bhargava, Fancourt, Craig, Thornton, Bob, Morrow, Linda, Kaarsholm, Niels C., Bernstein, Harold S., Stoch, S. Aubrey, Crutchlow, Michael, Kelley, David E., Iwamoto, Marian

“…The goal of this investigation was to examine clinical translation of glucose responsiveness of MK‐2640, which is a novel insulin saccharide conjugate that can…”
Get full text